Discover and read the best of Twitter Threads about #BetaDrugs
Most recents (3)
#betadrugs
AR FY21-22
MY TWO CENT .
If you like please RT
Second wave of COVID 19 impacted lives ,bussiness across the board.
We have also started to see inflation across economic in the world, interest rate increase & with ukrarian war conflict,supply chain constraints.
AR FY21-22
MY TWO CENT .
If you like please RT
Second wave of COVID 19 impacted lives ,bussiness across the board.
We have also started to see inflation across economic in the world, interest rate increase & with ukrarian war conflict,supply chain constraints.
2/n
Even the world experienced chaos and disruption, we delivered our highest growth .
FY22 revenues grew by 58% to 183.84 crores while consolidated EBITDA grew by 72% to Rs 43.5 crore from 25.24 compared with the year ago period. EBITDA margins expanded to 23.6 % from 21.7%
Even the world experienced chaos and disruption, we delivered our highest growth .
FY22 revenues grew by 58% to 183.84 crores while consolidated EBITDA grew by 72% to Rs 43.5 crore from 25.24 compared with the year ago period. EBITDA margins expanded to 23.6 % from 21.7%
3/n
Net profit too increased by 112% to Rs 24.8crores from Rs 11.7 crores compared with the same period a year ago.
#betadrugs commands a strong position in the Indian market with more than 112 SKUs and its products are available across all major Corporate & Govt hospitals.
Net profit too increased by 112% to Rs 24.8crores from Rs 11.7 crores compared with the same period a year ago.
#betadrugs commands a strong position in the Indian market with more than 112 SKUs and its products are available across all major Corporate & Govt hospitals.
Beta Drugs – SME Co
Co Overview: Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. As per Co’s website, it is aiming to launch 25 new products by 2026. It's manufacturing facilities consist of an API & formulation plants
#stock
Co Overview: Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. As per Co’s website, it is aiming to launch 25 new products by 2026. It's manufacturing facilities consist of an API & formulation plants
#stock
Leadership: After the demise of Late Shri Vijay Batra (Founder), the next generation of the Family has taken over the Leadership Role – Mr. Rahul Batra Chairman & Managing Director (Looks very aggressive in strategies to Me)
#StockMarket
#stock
#stockstowatch
#StockMarket
#stock
#stockstowatch
Business Overview:
1. Domestic Market: Beta Drugs develops and commercialize high quality & cost effective complex oncology drugs. Beta Drugs has a leadership position in Indian Oncology Market with 100 SKU's.
#StocksInFocus
#StockMarket
#stock
1. Domestic Market: Beta Drugs develops and commercialize high quality & cost effective complex oncology drugs. Beta Drugs has a leadership position in Indian Oncology Market with 100 SKU's.
#StocksInFocus
#StockMarket
#stock
On 29th April, @niftygranmaster added #BetaDrugs to his portfolio. The first SME stock. He had posted on 24th about the potential of companies, working on cancer cure. Let’s now take a deeper look at Beta Drugs and review its growth potential
2/ The company’s growth has indeed taken off in FY22.
FY 2018 - Rs.50 Crores
FY 2019 - Rs.64 Crores
FY 2020 - Rs.90 Crores
FY 2021 - Rs.116 Crores
FY 2022 - Rs.183 Crores
Net profit in FY22 more than doubled to Rs.25Crore with EPS at Rs.26.
FY 2018 - Rs.50 Crores
FY 2019 - Rs.64 Crores
FY 2020 - Rs.90 Crores
FY 2021 - Rs.116 Crores
FY 2022 - Rs.183 Crores
Net profit in FY22 more than doubled to Rs.25Crore with EPS at Rs.26.
3/ Beta Drugs had fully acquired Adley Formulation Pvt Ltd (AFPL) and Adley Lab Ltd (ADL) resulting in backward integration of APIs & other raw materials. This has made key difference in its operating margins and revenues.
